ArticleCardiovascular drugs and therapy2026
Amiodarone for the Management of Acute Atrial Arrhythmias After Lung Transplant.
Article in Cardiovascular drugs and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeDosing, safety, and outcomes of amiodarone in acute post-operative atrial arrhythmias (POAAs) after lung transplantation are not well understood. Current literature suggests amiodarone may increase mortality in lung transplant recipients (LTRs). This study described outcomes associated with amiodarone use in POAAs after lung transplantation.
methodsThis single-center, retrospective cohort study analyzed LTRs who received amiodarone after developing a POAA within 30 days of transplant surgery and prior to hospital discharge from their index transplant admission. Primary safety outcomes included mortality and the incidence of adverse drug reactions (ADRs). Secondary efficacy outcomes included time to normal sinus rhythm (NSR) attainment, intensive care unit (ICU) and hospital length of stay, and atrial arrhythmia (AA) recurrence.
resultsA total of 131 LTRs who developed an acute POAA received amiodarone. The 1-year mortality did not differ between this cohort and our overall lung transplant population, and ADR incidence was similar to that observed in non-LTRs. The median time to NSR attainment was 28 h after amiodarone initiation; ICU and hospital lengths of stay were 4.5 and 18.5 days, respectively; and AA recurrence occurred in 32.8% of patients.
conclusionThe findings of this study suggest that amiodarone use may be safe in LTRs with acute atrial arrhythmias, and may also effectively terminate acute POAAs in this population.
Indexed as
Identifiers
40445513What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.